Skip to main content
. 2014 Sep 5;289(42):29014–29029. doi: 10.1074/jbc.M114.602474

FIGURE 2.

FIGURE 2.

Extended pharmacodynamic and pharmacokinetic lifespan of PAS-YNSα8. a, transgenic mice expressing the luciferase reporter gene under the control of the IFN-responsive MX2 promoter (MX2-LUC) were interbred with HyBNAR mice and injected intraperitoneally with 1 μg (IFN component) of either PASylated or non-PASylated YNSα8. At different time points, mice were injected with luciferin and anesthetized, and in vivo luminosity was measured by an image-capturing device (IVIS spectrum). Representative time course images from a mouse injected with PAS-YNSα8 (I, left panels) or a mouse injected with YNSα8 (II, right panels) are shown. b, quantification of in vivo luciferase signal from triplicate mice for each injection group. The data were fitted to a double exponential to model the biodistribution and elimination of the cytokine evoking the luciferase signal. c, mice were injected with 0.25 or 1 μg of PASylated YNSα8 (active IFN), and serum was collected 6, 24, and 48 h after injection. For control, 1.0 μg of human IFNβ was similarly injected, with serum collected at 6 and 24 h. The serum was then functionally quantified for human IFN by an anti-viral assay in human WISH cells.